Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to
Plasmodium falciparum
CS Compared to That with Either Malaria Vaccine Alone
-
Published:2007-05
Issue:5
Volume:75
Page:2283-2290
-
ISSN:0019-9567
-
Container-title:Infection and Immunity
-
language:en
-
Short-container-title:Infect Immun
Author:
Stewart V. Ann1, McGrath Shannon M.1, Dubois Patrice M.2, Pau Maria G.3, Mettens Pascal2, Shott Joseph1, Cobb Michelle1, Burge J. Robert4, Larson David1, Ware Lisa A.1, Demoitie Marie-Ange2, Weverling Gerrit Jan3, Bayat Babak2, Custers Jerome H. H. V.3, Dubois Marie-Claude2, Cohen Joe2, Goudsmit Jaap3, Heppner D. Gray1
Affiliation:
1. Division of Malaria Vaccine Development 2. GlaxoSmithKline Biologicals, Rixensart, Belgium 3. Crucell Holland BV, Leiden, The Netherlands 4. Division of Biometrics, Walter Reed Army Institute of Research, Silver Spring, Maryland
Abstract
ABSTRACT
The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with
Plasmodium falciparum
malaria and also against clinical malaria and severe disease in children in areas of endemicity. Here we demonstrate with rhesus macaques that priming with a replication-defective human adenovirus serotype 35 (Ad35) vector encoding circumsporozoite protein (CS) (Ad35.CS), followed by boosting with RTS,S in an improved MPL- and QS21-based adjuvant formulation, AS01B, maintains antibody responses and dramatically increases levels of T cells producing gamma interferon and other Th1 cytokines in response to CS peptides. The increased T-cell responses induced by the combination of Ad35.CS and RTS,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more durable protection against
P. falciparum
infection in humans.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Immunology,Microbiology,Parasitology
Reference42 articles.
1. Alonso, P., J. Sacarlal, J. Aponte, A. Leach, E. Macete, P. Aide, B. Sigauque, J. Milman, I. Mandomando, Q. Bassat, C. Guinovart, M. Espasa, S. Corachan, M. Lievens, M. Navia, M. Dubois, C. Menendez, F. Dubovsky, J. Cohen, R. Thompson, and W. Ballou. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet366:2012-2018. 2. Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M. M. Navia, S. Corachan, M. Ceuppens, M. C. Dubois, M. A. Demoitie, F. Dubovsky, C. Menendez, N. Tornieporth, W. R. Ballou, R. Thompson, and J. Cohen. 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364:1411-1420. 3. Barouch, D. H., and G. J. Nabel. 2005. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther.16:149-156. 4. Boyson, J. E., C. Shufflebotham, L. F. Cadavid, J. A. Urvater, L. A. Knapp, A. L. Hughes, and D. I. Watkins. 1996. The MHC class I genes of the rhesus monkey. Different evolutionary histories of MHC class I and II genes in primates. J. Immunol.156:4656-4665. 5. Bruna-Romero, O., G. Gonzalez-Aseguinolaza, J. C. Hafalla, M. Tsuji, and R. S. Nussenzweig. 2001. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA98:11491-11496.
Cited by
97 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|